COMBO II Study — LDL-C Efficacy 75 mg/150 mg (vs ezetimibe)

On top of maximally tolerated statins,

PRALUENT® (alirocumab): Powerful LDL-C reduction at the recommended starting dose of 75 mg Q2W vs ezetimibe1

48% additive LDL-C reduction from baseline achieved at 24 weeks* vs 20% reduction for ezetimibe in the COMBO II study1

82% of patients in the COMBO II study achieved LDL-C goal (<70 mg/dL) at week 8 and did not require up-titration at week 12

Rapid LDL-C reduction with PRALUENT was sustained over 52 weeks

  • In COMBO II, adverse reactions occurring in ≥5% of PRALUENT-treated patients and more frequently than with ezetimibe were accidental overdose, upper respiratory tract infection, hypertension, headache, and arthralgia1
  • COMBO II was the largest ezetimibe-controlled study in the PRALUENT clinical program
    – 95% of patients had clinical ASCVD

NEXT: PRALUENT LDL-C Efficacy 300 mg Q4W/150 mg Q2W

Reference:
  1. Data on file, Sanofi/Regeneron.

Download Resources